BioCentury
ARTICLE | Company News

Gilead, Boehringer Ingelheim, AIDS Healthcare Foundation sales and marketing update

June 9, 2008 7:00 AM UTC

According to the foundation, Gilead and Boehringer committed to suspend increases in the prices of their HIV drugs for government agencies. The foundation wrote to nine companies to request price freezes in March. The foundation said Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.), Pfizer Inc. (NYSE:PFE, New York, N.Y.), Roche (SWX:ROG, Basel, Switzerland) and Tibotec Therapeutics “reiterated the companies' commitment to increasing access” but did not make any commitment to suspend price increases. The foundation said it has yet to hear from Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) or Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.). Tibotec is a subsidiary of Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). ...